Grifols, S.A. (NASDAQ:GRFS) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• Grifols, S.A. has received a consensus rating of "Moderate Buy" from five brokerages, with an average 12-month price objective of $10.30.
• Recent hedge fund activity includes Sequoia Financial Advisors boosting its stake by 14.9% and GAMMA Investing increasing its holdings by 426.1% during the first quarter.
• The company has recently declared a special dividend of $0.1404, with a payout ratio currently at 11.97%.

Grifols, S.A. (NASDAQ:GRFS - Get Free Report) has received a consensus rating of "Moderate Buy" from the five ratings firms that are currently covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation, one has given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $10.30.

GRFS has been the topic of a number of research analyst reports. Wall Street Zen upgraded shares of Grifols from a "buy" rating to a "strong-buy" rating in a research report on Monday, July 7th. Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Grifols in a research note on Tuesday, August 5th. JPMorgan Chase & Co. raised their target price on shares of Grifols from $7.60 to $10.30 and gave the company a "neutral" rating in a research note on Tuesday, June 17th. Finally, Zacks Research raised shares of Grifols to a "hold" rating in a research note on Friday, August 8th.

Hedge Funds Weigh In On Grifols

Large investors have recently made changes to their positions in the company. Sequoia Financial Advisors LLC boosted its stake in shares of Grifols by 14.9% during the 1st quarter. Sequoia Financial Advisors LLC now owns 26,230 shares of the biotechnology company's stock worth $186,000 after purchasing an additional 3,399 shares during the period. First Trust Advisors LP bought a new stake in shares of Grifols in the 4th quarter valued at about $75,000. GAMMA Investing LLC raised its holdings in shares of Grifols by 426.1% in the 1st quarter. GAMMA Investing LLC now owns 26,087 shares of the biotechnology company's stock valued at $1,850,000 after purchasing an additional 21,128 shares in the last quarter. Credit Industriel ET Commercial purchased a new stake in Grifols during the fourth quarter valued at approximately $4,537,000. Finally, Oppenheimer Asset Management Inc. lifted its position in Grifols by 66.5% during the first quarter. Oppenheimer Asset Management Inc. now owns 60,063 shares of the biotechnology company's stock valued at $427,000 after acquiring an additional 23,980 shares during the last quarter.

Grifols Trading Down 0.2%

Shares of NASDAQ GRFS opened at $10.11 on Tuesday. The company has a market cap of $6.95 billion, a PE ratio of 8.64, a P/E/G ratio of 0.34 and a beta of 0.64. The firm's 50 day moving average price is $10.03 and its 200-day moving average price is $8.59. Grifols has a 52-week low of $6.19 and a 52-week high of $11.14. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.95 and a current ratio of 2.64.

Grifols Dividend Announcement

The firm also recently disclosed a special dividend, which was paid on Wednesday, August 20th. Shareholders of record on Tuesday, August 12th were paid a $0.1404 dividend. The ex-dividend date of this dividend was Tuesday, August 12th. Grifols's dividend payout ratio (DPR) is presently 11.97%.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.